Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance

The long-term effectiveness of targeted cancer therapies is limited by the development of resistance. Although epigenetic reprogramming has been implicated in resistance, the mechanisms remain elusive. Herein, we demonstrate that increased chromatin accessibility is involved in adaptive BRAF inhibit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhiquan Wang, Rentian Wu, Qian Nie, Kelly J. Bouchonville, Robert B. Diasio, Steven M. Offer
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Targeted therapy BRAF inhibitor Adaptive drug resistance Chromatin assembly factor 1 Nucleosome assembly H3K9me3 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/accd85a0450f4044aac0532324b3811d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:accd85a0450f4044aac0532324b3811d
record_format	dspace
spelling	oai:doaj.org-article:accd85a0450f4044aac0532324b3811d2021-12-01T05:06:29ZChromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance2667-005410.1016/j.jncc.2020.12.003https://doaj.org/article/accd85a0450f4044aac0532324b3811d2021-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S266700542100003Xhttps://doaj.org/toc/2667-0054The long-term effectiveness of targeted cancer therapies is limited by the development of resistance. Although epigenetic reprogramming has been implicated in resistance, the mechanisms remain elusive. Herein, we demonstrate that increased chromatin accessibility is involved in adaptive BRAF inhibitor (BRAFi)-resistance in melanoma cells. We observed loss of chromatin assembly factor 1 (CAF-1) and its related histone H3 lysine 9 trimethylation (H3K9me3) with adaptive BRAFi resistance. We further showed that depletion of CAF-1 provides chromatin plasticity for effective reprogramming by AP1 components to promote BRAFi resistance. Our data suggest that therapeutic approaches to restore H3K9me3 levels may compensate for the loss of CAF-1 and, in turn, suppress resistance to BRAF inhibitors.Zhiquan WangRentian WuQian NieKelly J. BouchonvilleRobert B. DiasioSteven M. OfferElsevierarticleTargeted therapyBRAF inhibitorAdaptive drug resistanceChromatin assembly factor 1Nucleosome assemblyH3K9me3Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal of the National Cancer Center, Vol 1, Iss 1, Pp 15-22 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Targeted therapy BRAF inhibitor Adaptive drug resistance Chromatin assembly factor 1 Nucleosome assembly H3K9me3 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Targeted therapy BRAF inhibitor Adaptive drug resistance Chromatin assembly factor 1 Nucleosome assembly H3K9me3 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Zhiquan Wang Rentian Wu Qian Nie Kelly J. Bouchonville Robert B. Diasio Steven M. Offer Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
description	The long-term effectiveness of targeted cancer therapies is limited by the development of resistance. Although epigenetic reprogramming has been implicated in resistance, the mechanisms remain elusive. Herein, we demonstrate that increased chromatin accessibility is involved in adaptive BRAF inhibitor (BRAFi)-resistance in melanoma cells. We observed loss of chromatin assembly factor 1 (CAF-1) and its related histone H3 lysine 9 trimethylation (H3K9me3) with adaptive BRAFi resistance. We further showed that depletion of CAF-1 provides chromatin plasticity for effective reprogramming by AP1 components to promote BRAFi resistance. Our data suggest that therapeutic approaches to restore H3K9me3 levels may compensate for the loss of CAF-1 and, in turn, suppress resistance to BRAF inhibitors.
format	article
author	Zhiquan Wang Rentian Wu Qian Nie Kelly J. Bouchonville Robert B. Diasio Steven M. Offer
author_facet	Zhiquan Wang Rentian Wu Qian Nie Kelly J. Bouchonville Robert B. Diasio Steven M. Offer
author_sort	Zhiquan Wang
title	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
title_short	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
title_full	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
title_fullStr	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
title_full_unstemmed	Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
title_sort	chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/accd85a0450f4044aac0532324b3811d
work_keys_str_mv	AT zhiquanwang chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance AT rentianwu chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance AT qiannie chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance AT kellyjbouchonville chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance AT robertbdiasio chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance AT stevenmoffer chromatinassemblyfactor1suppressesepigeneticreprogrammingtowardadaptivedrugresistance
_version_	1718405564377071616

Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance

Ejemplares similares